ArticleJournal of applied toxicology : JAT2026
Fertility and Early Embryonic Development Toxicity of hzVSF-v13 in Sprague-Dawley Rats.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fertility and Early Embryonic Development Toxicity of hzVSF-v13 in Sprague-Dawley Rats.Journal of applied toxicology : JAT · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Humanized virus suppressing factor-variant 13 (hzVSF-v13), a monoclonal IgG4 antibody, is a potential therapeutic candidate for COVID-19. Although fertility and embryonic developmental toxicity studies are crucial for the safety evaluation of new drugs, the toxicological profile of hzVSF-v13 remains unexplored. This study was performed to assess its effects on general toxicity, fertility, and early embryonic development in Sprague-Dawley rats administered intravenously once weekly at doses of 0, 25, 50, and 100 mg/kg. Males received the test article starting 4 weeks before mating and continuing until the day prior to sacrifice, while females were treated beginning 2 weeks prior to mating and continuing through the implantation. No treatment-related effects were observed on general toxicological parameters, including body weight, food consumption, macroscopic findings, or organ weights in both sexes. Additionally, hzVSF-v13 did not affect the mating performance, fertility, sperm analysis, or litter parameters in cesarean section at doses up to 100 mg/kg. Under the experimental conditions, the no-observed-adverse-effect level (NOAEL) of hzVSF-v13 for general toxicity, fertility, and early embryonic development was considered to be 100 mg/kg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.